Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

Abstract

We thank for the comments from Wu et al. (1) on our research (2), comparison between trabectedin and doxorubicin in soft-tissue sarcomas. Reviewer Wu et al. said that in Table 1, we reported that 80 patients were included, which was inconsistent with the original study (3). In addition, Figure 6 showed the wrong data that the disease control rate of 54 of 75 patients in the experimental group and 41 of 39 patients in the control group lead to the inability to estimate the odds ratio (OR). We appreciate the suggestions. In Table 1, we listed the Hartmann's study (3) and we corrected the samples in Table 1 from (2). We now correct the Figure 6 of our research (2) since the mistake in typing the number (Figure 1).They also said that the authors conducted the sensitivity analysis only by omitting Schöffski et al.'s study (4) and did not further exclude the other included studies. Since the sensitivity was conducted by removing each study in term and selecting the most obvious change one, we only reported the result omitting Schöffski et al.'s study, which is the most obvious change article. Other included researches had smaller influence on the I 2 value than Schöffski et al.'s study.